Adaptive Biotechnologies Corp (ADPT) — SEC Filings
Adaptive Biotechnologies Corp (ADPT) — 32 SEC filings. Latest: 8-K (Dec 30, 2025). Includes 9 8-K, 6 10-Q, 6 SC 13G.
View Adaptive Biotechnologies Corp on SEC EDGAR
Overview
Adaptive Biotechnologies Corp (ADPT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 30, 2025: Adaptive Biotechnologies Corporation filed an 8-K on December 30, 2025, reporting other events. The company, incorporated in Washington with its principal executive offices in Seattle, operates in the biological products sector.
Sentiment Summary
Across 32 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 29 neutral. The dominant filing sentiment for Adaptive Biotechnologies Corp is neutral.
Filing Type Overview
Adaptive Biotechnologies Corp (ADPT) has filed 9 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 6 SC 13G, 6 SC 13G/A, 1 DEFA14A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (32)
Risk Profile
Risk Assessment: Of ADPT's 20 recent filings, 1 were flagged as high-risk, 9 as medium-risk, and 10 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $93.973M |
| Net Income | $9.545M |
| EPS | $0.06 |
| Cash Position | $55.034M |
| Total Assets | $490.610M |
Key Executives
- Dr. Jessica S. Markowitz
- Dr. Lance D. Carder
- Dr. Jessica M. Lang
- Ms. Jennifer D. D. Fox
Industry Context
Adaptive Biotechnologies operates in the rapidly evolving fields of diagnostics and immune medicine. The industry is characterized by significant scientific innovation, increasing demand for personalized medicine, and a complex regulatory landscape. Key trends include the advancement of genomic sequencing technologies and the growing importance of understanding the immune system for disease diagnosis and treatment.
Top Tags
10-Q (4) · Biotechnology (3) · biotechnology (3) · Adaptive Biotechnologies (3) · 8-K (2) · Diagnostics (2) · Immune Medicine (2) · 8-k (2) · shareholder-vote (2) · corporate-governance (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| SEC File Number | 001-38957 | Identifies the company's filing with the SEC. |
| IRS Employer Identification No. | 27-0907024 | Company's tax identification number. |
| Revenue for Q3 2025 | $93.973M | Increased from $46.435M in Q3 2024, representing a 102% increase. |
| Net income for Q3 2025 | $9.545M | Significant turnaround from a net loss of $32.097M in Q3 2024. |
| Net loss for the nine months ended Sept 30, 2025 | $45.878M | Reduced from a net loss of $125.878M in the prior year period. |
| Cash and cash equivalents as of Sept 30, 2025 | $55.034M | Increased from $47.920M at December 31, 2024. |
| Accumulated deficit as of Sept 30, 2025 | $1.349B | Indicates historical losses despite recent quarterly profit. |
| Total operating expenses for Q3 2025 | $83.683M | Increased from $79.067M in Q3 2024. |
| Sales and marketing expenses for Q3 2025 | $23.470M | Increased from $20.551M in Q3 2024, reflecting commercialization efforts. |
| Basic and diluted net income per share for Q3 2025 | $0.06 | Positive EPS compared to $(0.22) in Q3 2024. |
| Total Revenue | $38.9M | Decreased from $40.1M in Q2 2024 |
| Net Loss | $55.3M | Widened from $50.1M in Q2 2024 |
| MRD Business Segment Revenue | $25.2M | Contribution to Q2 2025 total revenue |
| Immune Medicine Business Segment Revenue | $13.7M | Contribution to Q2 2025 total revenue |
| Research and Development Expenses | $45.6M | Increased from $42.1M in Q2 2024 |
Frequently Asked Questions
What are the latest SEC filings for Adaptive Biotechnologies Corp (ADPT)?
Adaptive Biotechnologies Corp has 32 recent SEC filings from Jan 2024 to Dec 2025, including 9 8-K, 6 10-Q, 6 SC 13G. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ADPT filings?
Across 32 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 29 neutral. The dominant sentiment is neutral.
Where can I find Adaptive Biotechnologies Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Adaptive Biotechnologies Corp (ADPT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Adaptive Biotechnologies Corp?
Key financial highlights from Adaptive Biotechnologies Corp's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ADPT?
The investment thesis for ADPT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Adaptive Biotechnologies Corp?
Key executives identified across Adaptive Biotechnologies Corp's filings include Dr. Jessica S. Markowitz, Dr. Lance D. Carder, Dr. Jessica M. Lang, Ms. Jennifer D. D. Fox.
What are the main risk factors for Adaptive Biotechnologies Corp stock?
Of ADPT's 20 assessed filings, 1 were flagged high-risk, 9 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from Adaptive Biotechnologies Corp?
Forward guidance and predictions for Adaptive Biotechnologies Corp are extracted from SEC filings as they are enriched.